Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Almonertinib Combined With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis: A Prospective, Open-label, Multi-center, Single-arm Study

NCT04944069 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Nanchang University as lead sponsor.

NCT NCT04944069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04944069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Almonertinib Combined With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis: A Prospective, Open-label, Multi-center, Single-arm Study
Lead sponsor
Second Affiliated Hospital of Nanchang University
Phase
Not applicable
Overall status
Unknown status
Start date
July 31, 2021
Completion date
March 31, 2025
Enrollment
69 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, leptomeningeal metastasis, nsclc